Wednesday, May 11, 2011 8:56:02 AM
7:31AM Oncolytics Biotech has entered into a commercial supply agreement with SAFC, a division of Sigma-Aldrich (SIAL), for the commercial manufacture of REOLYSIN (ONCY) 70.57 : Co announces that it has entered into a commercial supply agreement with SAFC, a Division of Sigma-Aldrich (SIAL), for the commercial manufacture of REOLYSIN, Oncolytics proprietary reovirus. Under the terms of the agreement, SAFC will perform process validation of the product, will continue to supply clinical requirements and will supply commercial material upon approval of the product.
Recent ONCY News
- Form F-10POS - Post-effective amendment to a F-10EF registration • Edgar (US Regulatory) • 04/06/2026 09:20:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 08:12:51 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/06/2026 08:11:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 01:24:53 PM
- Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer • GlobeNewswire Inc. • 04/06/2026 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/06/2026 04:15:22 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 01:07:26 PM
- Oncolytics Biotech® Completes Domicile Change to the United States • GlobeNewswire Inc. • 04/01/2026 01:00:00 PM
- Form F-10POS - Post-effective amendment to a F-10EF registration • Edgar (US Regulatory) • 04/01/2026 01:57:29 AM

